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Although several molecular markers have been proposed as prognostic of disease progression in Hepatocellular
carcinoma (HCC), predictive markers of response to treatment are still unsatisfactory. Here, we propose a genetic
polymorphism as a potential predictive factor of poor prognosis in HCC patients treated with transcatheter arterial
chemoembolization (TACE). In particular, we show that the guanosine insertion/deletion polymorphism in the promoter
regionofSERPINE1geneat the−675bpposition, named4G/4G, predicts poor prognosis in a cohort of 75 patientswith
HCC undergoing TACE. By a combination of ELISA and SERPINE1 promoter study, we found that the presence of
elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1) in patients with 4G/4G genotype is significantly
associated with reduced overall survival compared to patients with 5G/5G or 4G/5G genotype in HCC patients after
TACE. Our analysis provided evidence that variation in SERPINE1 gene plays a role in defining the outcome in patients
treatedwith TACE. In addition to a poor disease outcome, the 4G/4G variant represents an unfavorable predictive factor
for response to chemotherapy as well.
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Many Hepatocellular carcinomas are diagnosed in intermediate or
advanced stages only when locoregional or palliative treatments are
feasible. The long-term survival of Hepatocellular carcinoma (HCC)
patients treated with locoregional or palliative treatments remains
unsatisfactory because the treated tumor frequently maintains residual
viability, leading to disease reactivation, although the survival rate can be
good in properly selected patients and under standardized condi-
tions [1,2]. Identifying biologic markers capable of predicting the
response to treatment in HCC patients may facilitate the disease’s
management. Serine protease (Serpins) inhibitors including plasmin-
ogen activator inhibitor-1 (PAI-1) play an important role in regulating a
wide array of diverse biologic activities, representing up to 2% to 10%of
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Figure 1. The BCLC staging system for HCC. M, metastasis; N, node; PS, performance status; RFA, radiofrequency ablation.
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coagulation (thrombosis and thrombolysis), neurotrophic factors,
hormone transport, complement and inflammation, angiogenesis,
hormone transport, and blood pressure among many other biologic
reactions [4,5]. Select serpins have been associated with progression
or remission of selected cancers, making them valuable for therapeutic
or diagnostic use [6,7]. PAI-1, the main regulator of thrombolysis,
displays the potential to either reduce or accelerate tumor growth;
however, the blockade of PAI-1 has recently been reported to reduce
cancer cell migration, proliferation, and survival through modulating
the function of urokinase-type plasminogen activator receptor [8].
As a potential prognostic factor, the concept of germline variation
imparting interindividual variability in tumor development, progres-
sion, and metastasis is receiving increasing attention. In vitro studies
suggest that cytokines, growth factors, and hormones can affect
PAI-1; however, the genetic and environmental determinants of
SERPINE1 expression are not fully understood [9,10]. Gene
variability may also contribute to the level of SERPINE1 biosynthesis
[11]. The human SERPINE1 gene is located on chromosome 7. A
guanosine insertion/deletion polymorphism in the promoter region of
SERPINE1 gene at the −675 bp position, named 4G/5G
(rs1799889), has been reported [12]. Recent studies indicate that
the protein encoded by the 4G-allele possesses higher activity than
that encoded by the 5G-allele. This is because the 5G-allele contains
an additional binding site for a DNA-binding protein that acts as a
transcriptional repressor [13,14]. Studies carried out in different
populations have consistently shown that individuals, homozygous
for the 4G-allele, have significantly higher plasma SERPINE1 levels
than those homozygous for the 5G-allele [15,16]. The role of PAI-1as a predictive factor of outcome in patients with HCC, and in
particular in patients treated with transcatheter arterial chemoemboliza-
tion (TACE), is poorly investigated. In a previous study, we investigated
the distribution of genotypes and the frequency of alleles of the 4G/5G
polymorphism in patients with HCC and the influence of the 4G/5G
polymorphism on the circulating levels of SERPINE1. In the present
study, we extended this knowledge by assessing the prognostic
significance and clinical impact of plasma levels of PAI-1 in HCC
patients before (pre) and after (post) TACE treatment. In particular, we
evaluated the clinical impact of the SERPINE14G/4G genotype on
prognosis of patients with HCC undergoing chemoembolization.
Materials and Methods
Cancer Stadiation
The Barcelona Clinic Liver Cancer (BCLC) tumor staging
classification combines the stage of the liver disease, tumor stage,
clinical performance, and treatment options for HCC. For unresectable
HCC intermediate stage (BCLC stage B or Child-Pugh class A/B with
large or multifocal HCC, no vascular invasion, or extrahepatic spread),
the current standard treatment is TACE as reported in Figure 1.
Inclusion Criteria for TACE Treatment
Criteria for the inclusion of HCC patients suitable for treatment
with TACE are shown in Table 1, including patients with measurable
inoperable HCC, histologic proven, multinodular HCC with
intermediate grade stage A or B, with no vascular invasion or
extrahepatic spread, and monofocal patients with HCC N 5 cm in
advanced cirrhosis (stage C), who had not received prior systemic
treatments for HCC.
Table 1. Indications for TACE in HCC Patients
Diagnosis Patients with confirmed diagnosis on the basis of EASL consensus diagnostic criteria for HCC
Tumor status No extrahepatic localizations
No main PV thrombosis
Tumor involvement N50% of the liver parenchyma
Patients with HCC not suitable for curative treatments such as resection, liver transplantation, or percutaneous ablation according to
BCLC staging classification and treatment schedule
Ablation is the indicated treatment (early stage), but not if treatment is unfeasible or if patient has declined
Patients who demonstrate recurrence after potentially curative treatment (resection and percutaneous ablation) and who have clearly
measurable disease according to modified RECIST criteria or even after transplantation
Patient performance status Eastern Cooperative Oncology Group performance status b3 or Karnofsky score N70
Patient metabolic status Patients with well-preserved liver function (Child-Pugh class A/B) without encephalopathy and mild or severe ascites
Serum creatinine b2 mg/dl (177 μmol/l)
Platelet count N50,000/mm3
Prothrombin activity N50%
Doxorubicin related WBC N3000 cells per mm3; neutrophils N1500 cells per mm3; left ventricular ejection fraction N50%
EASL, European Association for the Study of the Liver; PV, Portal Vein; RECIST, Response Evaluation Criteria In Solid Tumors; WBCs, White blood cells.
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Using this protocol, from June 2007 to December 2010, TACE was
performed in 75 consecutive HCC patients, 56 males (74.6%) and 19
females (25.4%), aged from 45 to 87 years (median, 73 years) enrolled at
the Giovanni Paolo II National Cancer Institute (Bari, Italy).
Information about gender, age, etiology, histologic diagnosis of cancer,
score of liver disease according to Child-Pugh, serum levels of total
albumin, bilirubin, transaminase ALT and AST, creatinine and
α-fetoprotein at baseline, the Cancer of the Liver Italian Program score,
portal thrombosis, the presence of livermetastasis identified by ultrasound
with contrast medium, computed tomography (CT) scan of the
abdomen, and the type of locoregional treatment (TACE) were collected
from clinical charts of each patient (Table 2). No patient receiving TACE
treatment showed extrahepatic metastases, patency of the portal vein, or
altered liver function; the diagnosis of HCC was cyto-histologically
confirmed by echo-guided fine needle aspiration biopsy.
Sample Collection
Awritten consent was obtained from all patients before enrollment in the
study, and the Ethical Committee of the Giovanni Paolo II National Cancer
Institute approved the protocol, which was in accordance with the ethical
guidelines of the 1975Declaration ofHelsinki. From each participant to this
study, 5 ml of peripheral blood was collected in a Vacutainer system with
lithium-heparin. Whole blood samples (200 μl) were collected for DNA
extraction before any invasive procedures or therapy. For PAI-1 ELISA test,
the remaining part of the sample was centrifuged, and plasma was
immediately separated from the cellular fraction by centrifugation at 1500g
for 10 minutes and stored in microtubes (aliquots of 200 μl) and frozen
and at −20°C. Patients agreed to provide two blood samples: one before
TACE (pre) treatment and one after TACE (post) treatment, 4 to 6
weeks at the time of spiral CT.
TACE Procedure
Each patient was discussed in a team meeting to decide the appropriate
approach. Asymptomatic patients who had multinodular HCC in the
intermediate stage (A or B) with no vascular invasion or extrahepatic spread
and monofocal patients with HCC,N N 5 cm, in advanced cirrhosis (stage
C) were treated. This procedure has been previously described [17]. Briefly,
treatmentwithTACEwas performedwith a standard protocol under general
anesthesia by binding DC-Beads (Biocompatibles, Farnham, United
Kingdom) to a total dose of doxorubicin of 100 mg/50 ml and injecting
by percutaneously inserting a microcatheter into the femoral artery of the
patient under fluoroscopic guidance (X-ray) that corresponds tothe artery of the liver. When applicable, the artery feeding the
tumor was cannulated in a superselective approach. In the case of
bilobar tumor involvement, the chemoembolic agent was injected two
subsequent time points, after 30 and 60 days, starting with the lobe
more extensively involved. Efficacy was evaluated by dynamic CT 2 to 3
days after each treatment session, 1 month, 3 months, and 6 months,
and the sessions were repeated until an ablative margin was obtained.
SERPINE1 ELISA and SERPINE1 Promoter
4G/4G Polymorphism
These procedures have been previously described [7–18]. Plasma
SERPINE1 concentrations were determined with ELISA (Imunobind
Plasma PAI-1 ELISA; American Diagnostica GmbH, Pfungstadt,
Germany) according to the manufacturer’s recommendations. For SER-
PINE1 promoter 4G/4G polymorphism, briefly, after extraction of
genomic DNA from whole blood with QIAamp DNA blood mini kit
(Qiagen, Hilden, Germany), DNA was amplified for molecular detection
of SERPINE1 promoter 4G/5G polymorphism by an allele-specific
(polymerase chain reaction) analysis using specific primers as previously
described [7–18]. The polymerase chain reaction was carried out in a final
volumeof 25μl, and the amplifiedDNA fragmentswere separated by a 5%
polyacrylamide gel electrophoresis. Each study participant was classified
into one of the three possible genotypes: 4G/4G, 4G/5G, or 5G/5G.
Statistical Analysis
For the continuous variables, data were analyzed with the unpaired
t test as well as analysis of variance. The correlation between the PAI-1
plasma values before and after TACE treatment was evaluated using
the Student's t test. A P value ≤ .05 indicates statistical significance.
Overall survival (OS) was the end point of the survival analysis and
was estimated with Kaplan-Meier curves and tested with the log-rank
test. OS was defined as the time between the date of the blood sample
drawing and the date of death or the last follow-up examination. A P
value ≤ .05 indicates statistical significance. All statistical analyses were
performed byNumberCruncher Statistical System–Power Analysis and
Sample Size Software 2007 (NCSS-PASS, Kaysville, UT).Results
Evaluation of SERPINE1 Plasma Levels before and after
TACE Treatment
To compare the circulating plasma levels of PAI-1 in patients with
HCC before and after TACE, we carried out ELISAs on collected
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Figure 2. Circulating plasma levels of PAI-1 assayed before (pre)
and after (post) treatment with TACE.
Table 2. Clinical Characteristics of Patients
N Percentage
Control group 50
Patients 75
Gender
Male 56 75
Female 19 25
Virus infection
HCV+/HBV+ 27 36
HCV+/HBV− 19 25
HCV−/HBV− 29 39
Histologic type
Multinodular HCC stage A or B 60 80
Single nodule HCC, N N 5 cm (stage C) 10 20
AFP
b20 ng/ml 38 51
≥20 ng/ml 37 49
Tumor differentiation
Well (G1) 18 24
Moderate (G2) 23 31
Poor (G3) 34 45
Child-Pugh index
A 19 26
B 40 53
C 16 21
Blood Chemistry Parameters Range Median Value
Serum albumin 2.4-4.7 g/dl 3.1 g/dl
Serum bilirubin 0.37-4.50 mg/dl 0.95 mg/dl
Serum ALT 16-148 U/l 58.0 U/l
Serum AST 18-334 U/l 76.5 U/l
Serum creatinine 0.53-1.21 mg/dl 0.67 mg/dl
Serum AFP 6.2-4164 ng/ml 1672.7 ng/ml
Platelet 77 × 103 to 208 × 103 pl 169 × 103 pl
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tions of circulating PAI-1 after TACE (34.11 ± 30.5 ng/ml) compared
with those before TACE treatment (42.76 ± 25.8 ng/ml, P = .014;
Figure 2).
Elevated Circulating Plasma Levels of PAI-1 Are Associated
with the 4G/4G SERPINE1 Polymorphism
Since after TACE concentrations of PAI-1 remained elevated in a
number of patients (N = 32), we sought to evaluate whether
circulating plasma levels of PAI-1 were influenced by SERPINE1
genotype distribution before and after TACE. We therefore correlate
4G/5G polymorphism with the levels of PAI-1 in patients with HCC
before and after TACE. We observed that genotype 4G/4G (N = 32
patients) is associated with higher levels of PAI-1 without difference
before and after TACE (P = .175), whereas the alleles 4G/5G (N =
24) and 5G/5G (N = 19) are associated with high levels of PAI-1 in
plasma of patients before TACE compared to plasma from patients
after TACE (P b .0001, respectively; Figure 3). Thus, the genotype
influences the circulating plasma levels of PAI-1 in patients with
HCC before and after TACE.
4G/4G SERPINE1 Genotype Represents an Adverse Prognostic
Factor for Patients with HCC Undergoing TACE Treatment
To evaluate whether SERPINE1 genotype has a prognostic role in
these patients, we analyzed the OS with Kaplan-Meier analysis. The
analysis shows that patients harboring the 4G/4G genotype have a
poorer prognosis compared to 4G/5G and 5G/5G genotypes. Themedian OS was 9, 18, and 25 months in 4G/4G, 4G/5G, and 5G/5G
patient genotype groups, respectively (4G/4G vs 4G/5G, P = .05 and
4G/4G vs 5G/5G, P = .01, log-rank test; Figure 4). In addition, we
analyzed the OS according to the PAI-1 plasma levels. We found that
patients with elevated circulating levels of PAI-1 displays a poor
prognosis compared to those with lower circulating levels (Figure 5).
In fact, in patients with levels of PAI-1 above the cutoff value ≥35.5
ng/ml (35.5 ng/ml = median value), the OS was 15 months versus 28
months (P = .001, log-rank test), which was in contrast to that
observed in patients with levels lower than the cutoff value b35.5 ng/ml
(Figure 5). These findings corroborate our observations showing that
HCC patients with 4G/4G genotype and therefore with higher PAI-1
levels have decreased OS.
Discussion
To our knowledge, this is the first report investigating the influence of
SERPINE1 4G/4G polymorphism on the expression of plasma
SERPINE1 protein in patients with HCC undergoing TACE to
evaluate the prognostic significance in response to treatment. In
particular, we have shown that elevated circulating PAI-1 levels and
the presence of 4G/4G genotype influence the prognosis in HCC
patients who have undergone TACE. In our prospective evaluation,
we examined plasma concentrations of PAI-1 before TACE and,
subsequently, 4 to 6 weeks later, after TACE in 75 patients with
HCC. Analysis of collected data has confirmed that elevated plasma
levels of PAI-1 were found in patients before starting therapy, which
decreased (P = .01) after initiation of treatment. Surprisingly, in 32
patients, the plasma levels of PAI-1 remained elevated even after
TACE and these patients had a worse prognosis than patients with
decreased levels of PAI-1 after TACE. In our previous work, we found
that the frequency of the SERPINE1 4G allele was significantly
higher in patients with Hepatitis B virus (HBV) and Hepatitis C virus
(HCV) co-infection (N = 32) than in those with no viral infection
[19]. In line with this evidence, in this study, we found that 26 of 32
HCC patients had viral etiology (HCV/HBV) and these patients were
homozygous for the SERPINE1 4G allele with plasma level of
SERPINE1 significantly elevated compared to HCC patients without
viral infection (P b .001, analysis of variance). Studies carried out in
different populations have consistently shown that individuals
homozygous for the 4G allele have significantly higher plasma
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Figure 3. (A) Genotype distribution in HCC patients before (pre) and
after (post) treatment with TACE. (B) Circulating plasma levels of
PAI-1 assayed pre-treatment and post-treatment with TACE in
relation to SERPINE1 genotype.
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Figure 4. Kaplan-Meier survival analysis showing the relationship
between PAI-1 4G/4G genotype and prognosis from HCC.
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Figure 5. Differences in OS between HCC patients with low and
high circulating levels of PAI-1.
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fact, we observed that the presence of 4G/4G genotype with elevated
plasma levels of PAI-1 is significantly associated with reduced OS
compared to 5G/5G and 4G/5G genotypes.
As a potential prognostic factor, the concept of “germline
variation” imparting interindividual variability in tumor develop-
ment, progression, and metastasis is receiving increasing attention.
Our analysis provided evidence that variation in PAI-1 plays a role in
defining individual patient prognosis. Owing to its association with
poor disease outcome, the 4G/4G variant may represent an
unfavorable predictive factor for response to chemotherapy as well
[21]. If the unfavorable effect of the 4G/4G variant can be confirmed,
it may help identify no responders to chemotherapy, with curative
intent [22]. These data are interesting because a major problem in
prognostic outcome after locoregional treatment is the lack of
histopathologic features such as microscopic vascular invasion and
intrahepatic metastasis that are important prognostic factors after
resection or transplantation. The 4G/5G polymorphism of the
SERPINE1 gene has been extensively studied for associations with
cardiovascular disease; however, few studies have been conducted
regarding association with cancer [23,24]. Our working hypothesis is
that, as the presence of the 4G allele results in a higher SERPINE1
transcription in response to cytokines or growth factors than the 5G
allele, the 4G/5G polymorphism may influence circulating SER-
PINE1 protein levels in patients with HCC through the action of
cytokines released by tumor cells. The co-presence of 4G allele and
viral infection may also exert an unfavorable influence on tumor
progression. Therefore, circulating SERPINE1 may be useful as a
prognostic predictor for TACE therapy, particularly in patients with
4G/5G SERPINE1 genotype or in patients homozygous for the 5Gallele. While the importance of polymorphisms of PAI-1 in relation to
prognosis is growing, we suggest that PAI-1 may also be a potential
therapeutic target especially for those patients with 4G/4G genotype.
Our findings show that the genetic variation of PAI plays a role in the
prognosis of HCC. In addition, genetic variations of PAI could help
identify different models of outcome between patients with the same
clinical features of the disease, thus giving a rationale for treatment
based on a combination of genotype and tumor characteristics of a
patient. In conclusion, our findings provide evidence that inherited
variation influences the clinical outcome of HCC and indicate PAI-1
genetic variations as a prognostic marker. Further independent
replication studies based on unbiased data sets are, however, necessary
to confirm the general validity of our findings.
278 Prognosis prediction by PAI-1 in response to TACE Divella et al. Translational Oncology Vol. 8, No. 4, 2015References
[1] Abdel-Rahman O and Elsayed ZA (2013). Combination trans arterial
chemoembolization (TACE) plus sorafenib for the management of unresectable
hepatocellular carcinoma: a systematic review of the literature. Dig Dis Sci
58(12), 3389–3396.
[2] Wang J, He XD, Yao N, Liang WJ, and Zhang YC (2013). A meta-analysis of
adjuvant therapy after potentially curative treatment for hepatocellular
carcinoma. Can J Gastroenterol 27(6), 351–363.
[3] Zheng D, Chen H, Davids J, Bryant M, and Lucas A (2013). Serpins for
diagnosis and therapy in cancer. Cardiovasc Hematol Disord Drug Targets 13(2),
123–132.
[4] Dupont DM, Madsen JB, Kristensen T, Bodker JS, Blouse GE, Wind T, and
Andreasen PA (2009). Biochemical properties of plasminogen activator
inhibitor-1. Front Biosci (Landmark Ed) 14, 1337–1361.
[5] Lademann UA and Rømer MU (2008). Regulation of programmed cell death by
plasminogen activator inhibitor type 1 (PAI-1). Thromb Haemost 100(6),
1041–1046.
[6] Schmitt M, Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A,
Sweep F, Brünner N, Foekens J, and Harbeck N (2010). Clinical utility of
level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor
PAI-1. Expert Rev Mol Diagn 10(8), 1051–1067.
[7] Divella R, Lacalamita R, Tommasi S, Coviello M, Daniele A, Garrisi VM,
Abbate I, Simone G, Gadaleta C, and Paradiso A, et al (2008). PAI-1, t-PA and
circulating hTERT DNA as related to virus infection in liver carcinogenesis.
Anticancer Res 28(1A), 223–228.
[8] Van De Craen B, Declerck PJ, and Gils A (2013). The biochemistry, physiology
and pathological roles of PAI-1 and the requirements for PAI-1 inhibition in
vivo. Thromb Res 130(4), 576–585.
[9] Roca C, Primo L, Valdembri D, Cividalli A, Declerck P, and Carmeliet P (2003).
Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor
1-dependent mechanism. Cancer Res 63, 1500–1507.
[10] Kwaan HC andMcMahon B (2009). The role of plasminogen-plasmin system in
cancer. Cancer Treat Res 148, 43–66.
[11] Kutz SM, Hordines J, McKeown-Longo PJ, and Higgins PJ (2001).
TGF-β1-induced PAI-1 gene expression requires MEK activity and cell-to-sub-
strate adhesion. J Cell Sci 114, 3905–3914.
[12] Grancha S, Estelles A, Tormo F, Falco C, Gilabert J, and Espana F (1999).
Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and
increased PAI-1 circulating levels in postmenopausal women with coronary artery
disease. Thromb Haemost 81, 516–521.[13] Loskutoff DJ, Sawdey M, Keeton M, and Scheiderman J (1993). Regulation of
PAI-1 gene expression in vivo. Thromb Haemost 70, 135–137.
[14] Blasiak J, Smolarz B, Romanowicz-Macowska H, and Pertynski T (2000).
Polymorphisms of the promoter region of the plasminogen activator-1 (PAI-1)
gene in women with endometrial cancer. Pol J Gynaecol Invest 3, 611–666.
[15] Dawson SJ, Wiman B, Hamsten A, Green F, Humphiries S, and Henney AM
(1993). The two allele sequences of a common polymorphism in the promoter of
the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to
interleukin-1 in HepG2 cells. J Biol Chem 268, 10739–10745.
[16] Asselbergs FW, Pattin K, Snieder H, Hillege HL, van Gilst WH, and Moore JH
(2008). Genetic architecture of tissue-type plasminogen activator and plasmin-
ogen activator inhibitor-1. Semin Thromb Hemost 34(6), 562–568.
[17] Daniele A, Divella R, Quaranta M, Mattioli V, Casamassima P, Paradiso A,
Garrisi VM, Gadaleta CD, Gadaleta-Caldarola G, and Savino E, et al (2014).
Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in
HCC patients prior to and after trans-hepatic arterial chemo-embolization. Clin
Biochem 47(3), 184–190.
[18] Divella R, Mazzocca A, Gadaleta C, Simone G, Paradiso A, Quaranta M, and
Daniele A (2012). Influence of plasminogen activator inhibitor-1 (SERPINE1)
4G/5G polymorphism on circulating SERPINE-1 antigen expression in HCC
associated with viral infection. Cancer Genomics Proteomics 9(4), 193–198.
[19] Festa A, D’Agostino R, Rich SS, Jenny NS, Tracy RP, and Haffner SM (2003).
Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen
activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the
Insulin Resistance Atherosclerosis Study. Circulation 107, 2422–2427.
[20] Palmirotta R, Ferroni P, Savonarola A, Martini F, Ciatti F, Laudisi A, Sini V, Del
Monte G, Guadagni F, and Roselli M (2009). Prognostic value of pre-surgical
plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb
Res 124(4), 403–408.
[21] Yagmurdur MC, Atac FB, Tutar NU, Verdi H, Isiklar I, Ozdemir BH, Ozbek N,
Karakayali H, and Haberal M (2008). Prognostic value of the PAI-1 4G/5G
polymorphism in invasive ductal carcinoma of the breast. Int Surg 93(3), 163–168.
[22] Kinik ST, Ozbek N, Yuce M, Yazici AC, Verdi H, and Atac FB (2008). PAI-1
gene 4G/5G polymorphism, cytokine levels and their relations with metabolic
parameters in obese children. Thromb Haemost 99(2), 352–356.
[23] Kohler HP and Grant PJ (2000). Plasminogen-activator inhibitor type 1 and
coronary artery disease. N Engl J Med 342(24), 1792–1801.
[24] Huang J, Sabater-Lleal M, Asselbergs FW, Tregouet D, Shin SY, Ding J,
Baumert J, Oudot-Mellakh T, Folkersen L, and Johnson AD, et al (2012).
Genome-wide association study for circulating levels of PAI-1 provides novel
insights into its regulation. Blood 120(24), 4873–4881.
